IP Library Granted Patent US 10,745,274
Granted Patent B1
US 10,745,274 · App. 16/837,600 · Granted Aug 18, 2020

Nucleic acids encoding antibodies specifically binding to MASP-3

Inventors: W. Jason Cummings (Bellevue, WA); Gregory A. Demopulos (Mercer Island, WA); Thomas Dudler (Bellevue, WA); Larry W. Tjoelker (Kirkland, WA); Christi L. Wood (Snohomish, WA); Munehisa Yabuki (Seattle, WA)
Assignee: Omeros Corporation
B82Y25/00C01F17/206C09K11/77C09K11/7728H01F1/0054C01P2002/54C01P2002/84C01P2004/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,745,274
App. No.
16/837,600
Granted
Aug 18, 2020
Kind
B1
Abstract

The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

Claims (15)

1. A cloning or expression vector comprising a nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-3, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:254 or SEQ ID NO:255 and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:45, SEQ ID NO:256 or SEQ ID NO:280.

2. The cloning or expression vector of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO:254 and the light chain variable region comprises SEQ ID NO:45.

3. The cloning or expression vector of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO:254 and the light chain variable region comprises SEQ ID NO:256.

4. The cloning or expression vector of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO:254 and the light chain variable region comprises SEQ ID NO:280.

5. The cloning or expression vector of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO:255 and the light chain variable region comprises SEQ ID NO:45.

6. The cloning or expression vector of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO:255 and the light chain variable region comprises SEQ ID NO:256.

7. The cloning or expression vector of claim 1 , wherein the heavy chain variable region comprises SEQ ID NO:255 and the light chain variable region comprises SEQ ID NO:280.

8. A cell comprising the cloning or expression vector according to claim 1 .

9. A cell comprising:

(a) a nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-3, wherein the heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:255; and

(b) a nucleic acid encoding complementarity regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-3, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:280.

10. The cell of claim 9 , wherein the nucleic acid according to (a) and the nucleic acid according to (b) are included in an expression vector in the cell.

11. The cell of claim 9 , wherein the nucleic acid according to (a) and the nucleic acid according to (b) are included in different expression vectors in the cell.

12. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-3, the method comprising culturing the cell of claim 8 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid.

13. The method of claim 12 , further comprising isolating the antibody, or antigen-binding fragment thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2025
From: OMEROS CORPORATION
To: NOVO NORDISK HEALTH CARE AG
Reel/Frame 073916/0555 →
RELEASE OF SECURITY INTEREST Recorded Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE BOX TITLED"THIS DOCUMENT SERVES AS AN OATH/DECLARATION (37 CFR 1.63)" WAS ERRONEOUSLY CHECKED AND THIS BOX SHOULD NOT HAVE BEEN CHECKED, PREVIOUSLY RECORDED AT REEL: 67607 FRAME: 108. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Dec 11, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 069715/0719 →
SECURITY INTEREST Recorded Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →